Travere Therapeutics, Inc. TVTX
We take great care to ensure that the data presented and summarized in this overview for Travere Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TVTX
View all-
Armistice Capital, LLC New York, NY8.87MShares$145 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$125 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$123 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$81.9 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$78.3 Million0.11% of portfolio
-
State Street Corp Boston, MA3.65MShares$59.6 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.92MShares$47.7 Million3.13% of portfolio
-
Driehaus Capital Management LLC Chicago, IL2.77MShares$45.2 Million0.54% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.7MShares$44.1 Million0.08% of portfolio
-
Viking Global Investors LP2.6MShares$42.5 Million0.16% of portfolio
Latest Institutional Activity in TVTX
Top Purchases
Top Sells
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Transactions at TVTX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 01
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
815
-0.91%
|
$11,410
$14.65 P/Share
|
May 15
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+14.77%
|
-
|
May 15
2025
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+18.44%
|
-
|
May 15
2025
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+10.48%
|
-
|
May 15
2025
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+10.16%
|
-
|
May 15
2025
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+6.91%
|
-
|
May 15
2025
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+15.52%
|
-
|
May 15
2025
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.81%
|
-
|
May 15
2025
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+15.52%
|
-
|
May 15
2025
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+20.16%
|
-
|
May 05
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
4,920
-5.21%
|
$103,320
$21.05 P/Share
|
May 05
2025
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,198
-3.09%
|
$67,158
$21.05 P/Share
|
May 05
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,771
-1.36%
|
$37,191
$21.05 P/Share
|
May 05
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
18,924
-4.32%
|
$397,404
$21.05 P/Share
|
May 05
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,784
-1.88%
|
$37,464
$21.05 P/Share
|
May 02
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.95%
|
-
|
May 02
2025
|
William E. Rote Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.54%
|
-
|
May 02
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+3.65%
|
-
|
May 02
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,924
+4.14%
|
-
|
May 02
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 384K shares |
---|---|
Exercise of conversion of derivative security | 252K shares |
Open market or private sale | 399K shares |
---|